These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22543826)

  • 1. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
    Efficace F; Breccia M; Saussele S; Kossak-Roth U; Cardoni A; Caocci G; Chie W; Naeem A; Nicolatou-Galitis O; Cocks K; Vignetti M; Baccarani M; Mandelli F; Sprangers M
    Ann Hematol; 2012 Sep; 91(9):1371-81. PubMed ID: 22543826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
    Efficace F; Baccarani M; Breccia M; Cottone F; Alimena G; Deliliers GL; Baratè C; Specchia G; Di Lorenzo R; Luciano L; Turri D; Martino B; Stagno F; Dabusti M; Bergamaschi M; Leoni P; Simula MP; Levato L; Fava C; Veneri D; Sica S; Rambaldi A; Rosti G; Vignetti M; Mandelli F
    Leukemia; 2013 Jul; 27(7):1511-9. PubMed ID: 23417029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases.
    Harris K; Chow E; Zhang L; Velikova G; Bezjak A; Wu J; Barton M; Sezer O; Eek R; Shafiq J; Yee A; Clemons M; Brundage M; Hoskin P; van der Linden Y; Johnson CD; Bottomley A;
    Eur J Cancer; 2009 Sep; 45(14):2510-8. PubMed ID: 19635661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.
    Efficace F; Baccarani M; Breccia M; Saussele S; Abel G; Caocci G; Guilhot F; Cocks K; Naeem A; Sprangers M; Oerlemans S; Chie W; Castagnetti F; Bombaci F; Sharf G; Cardoni A; Noens L; Pallua S; Salvucci M; Nicolatou-Galitis O; Rosti G; Mandelli F
    Qual Life Res; 2014 Apr; 23(3):825-36. PubMed ID: 24026634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors.
    Efficace F; Rosti G; Cottone F; Breccia M; Castagnetti F; Iurlo A; Mandelli F; Baccarani M
    Leuk Res; 2014 Mar; 38(3):294-8. PubMed ID: 23906625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.
    Trask PC; Cella D; Besson N; Kelly V; Masszi T; Kim DW
    Leuk Res; 2012 Apr; 36(4):438-42. PubMed ID: 22036634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The challenge of the 'C' in CML.
    Mauro MJ
    Leuk Res; 2014 Mar; 38(3):286. PubMed ID: 24439564
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
    Kantarjian HM; Cortes J; Guilhot F; Hochhaus A; Baccarani M; Lokey L
    Cancer; 2007 Apr; 109(7):1365-75. PubMed ID: 17326047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and emerging treatment options in chronic myeloid leukemia.
    Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
    Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate for the treatment of chronic myeloid leukemia.
    Soverini S; Martinelli G; Iacobucci I; Baccarani M
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):853-64. PubMed ID: 18533795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
    Efficace F; Castagnetti F; Martino B; Breccia M; D'Adda M; Angelucci E; Stagno F; Cottone F; Malato A; Trabacchi E; Capalbo SF; Gobbi M; Visani G; Salvucci M; Capodanno I; Tosi P; Tiribelli M; Scortechini AR; Levato L; Maino E; Binotto G; Gugliotta G; Vignetti M; Baccarani M; Rosti G
    Cancer; 2018 May; 124(10):2228-2237. PubMed ID: 29499087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.
    Hess G; Meyer RG; Schuch B; Bechthold K; El-Kholy I; Huber C
    Am J Hematol; 2008 Mar; 83(3):178-84. PubMed ID: 17876770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
    Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
    Tauchi T; Kizaki M; Okamoto S; Tanaka H; Tanimoto M; Inokuchi K; Murayama T; Saburi Y; Hino M; Tsudo M; Shimomura T; Isobe Y; Oshimi K; Dan K; Ohyashiki K; Ikeda Y;
    Leuk Res; 2011 May; 35(5):585-90. PubMed ID: 21145591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [STI 571 for treating 19 patients with chronic-phase chronic myeloid leukemia].
    Meng FY; Zheng WY; Liu XL; Xu B; Song LL; Zhang Y; Huang F
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1149-50. PubMed ID: 14625174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country.
    Aziz Z; Iqbal J; Akram M; Saeed S
    Cancer; 2007 Mar; 109(6):1138-45. PubMed ID: 17315159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E; Ward S; Gordois A; Scuffham P
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The patient journey in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapies: qualitative insights using a global ethnographic approach.
    Guilhot F; Coombs J; Szczudlo T; Zernovak O; Paolantonio M; Bender C; Macdonald NJ; Shapiro A
    Patient; 2013; 6(2):81-92. PubMed ID: 23529848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.